Alpha-Fetoprotein (AFP)

Alpha-Fetoprotein (AFP) is a blood test that measures alpha-fetoprotein, a protein produced mainly by the developing fetal liver and yolk sac. AFP levels are normally high during fetal development and decrease significantly after birth. Healthy non-pregnant adults usually have low concentrations.

AFP is used as a tumour marker to support the evaluation and monitoring of hepatocellular carcinoma and selected germ-cell tumours. An AFP result cannot independently diagnose cancer and must be interpreted with symptoms, imaging, pathology, and other tumour markers.

Benefits of the Test

• Measures alpha-fetoprotein concentration in blood.
• Supports evaluation of suspected hepatocellular carcinoma.
• Helps assess selected testicular and ovarian germ-cell tumours.
• Provides a baseline result before cancer treatment.
• May help monitor response to surgery, chemotherapy, or other treatment.
• Supports follow-up for possible tumour recurrence.
• Can be interpreted with imaging and other tumour markers.
• May support liver-cancer surveillance in selected high-risk patients.
• Requires only a routine blood sample.
• Provides quantitative information for specialist interpretation.

Why Doctors Recommend This Test

Doctors may recommend AFP testing when liver imaging shows a suspicious mass, when a patient with chronic liver disease requires specialist-directed surveillance, or when symptoms and examination findings suggest a liver or germ-cell tumour.

The test may also be requested before treatment to establish a baseline and repeated afterward to assess response. In patients whose tumour produces AFP, rising levels during follow-up may lead to further investigation for persistent or recurrent disease.

Preparation Before Test

• No fasting is generally required unless instructed otherwise.
• A blood sample is collected from a vein for analysis.
• Inform the doctor if you are pregnant or may be pregnant.
• Share any history of hepatitis, cirrhosis, or chronic liver disease.
• Inform the doctor about previous or current cancer treatment.
• Provide details of all medicines, vitamins, and supplements.
• Do not stop prescribed medicines without medical advice.
• Carry previous AFP, liver-function, imaging, and biopsy reports.
• For monitoring, repeat testing may be performed using a comparable laboratory method.
• Follow any additional instructions provided by the treating specialist.

Normal Reporting Time

The Alpha-Fetoprotein (AFP) test is generally processed using a laboratory immunoassay. Results are commonly available on the same day or within 24 hours after sample collection, processing, analysis, validation, and quality review. Exact reporting time may vary according to sample timing and laboratory workflow.

Who Should Take This Test?

This test may be recommended for:

• Patients with a liver mass identified through imaging.
• Individuals being evaluated for hepatocellular carcinoma.
• Selected patients with cirrhosis or chronic hepatitis under surveillance.
• Men with a suspected testicular germ-cell tumour.
• Women with a suspected ovarian germ-cell tumour.
• Patients with a diagnosed AFP-producing cancer.
• Individuals requiring a baseline tumour-marker result before treatment.
• Patients undergoing monitoring during cancer treatment.
• Individuals undergoing follow-up for possible tumour recurrence.
• People specifically advised to undergo AFP testing by an oncologist or liver specialist.

Detailed Information

Alpha-fetoprotein is a glycoprotein produced in large quantities during fetal development. It performs functions similar to albumin in the developing fetus. After birth, AFP production normally falls, and adult concentrations become low.

Some cancer cells regain the ability to produce AFP. This occurs most notably in hepatocellular carcinoma, the most common primary cancer originating in the liver. AFP may also be produced by non-seminomatous germ-cell tumours, particularly those containing yolk-sac tumour components.

An elevated AFP result does not independently prove that cancer is present. Non-cancerous liver conditions such as acute hepatitis, chronic hepatitis, cirrhosis, and liver-cell regeneration may also increase AFP, usually to varying degrees.

Pregnancy naturally increases maternal AFP because the developing fetus produces the protein. Pregnancy status must therefore be considered when an adult AFP tumour-marker result is interpreted.

Not every hepatocellular carcinoma produces AFP. Some patients with confirmed liver cancer may have a result within the laboratory reference range. A normal AFP result therefore cannot exclude liver cancer.

AFP should not be used as a stand-alone screening test for cancer in people without appropriate clinical risk or findings. For selected patients with chronic liver disease, surveillance strategies generally rely on imaging, sometimes combined with AFP according to specialist guidance.

If liver cancer is suspected, doctors may interpret AFP with liver ultrasound, multiphase CT, MRI, liver-function tests, hepatitis markers, and clinical findings. A biopsy may be required in selected cases, although imaging can sometimes establish the diagnosis.

In germ-cell tumour evaluation, AFP may be interpreted with beta-human chorionic gonadotropin and lactate dehydrogenase. The marker pattern can support tumour classification, staging, risk assessment, and monitoring.

Pure seminoma does not normally produce AFP. An increased AFP result in a patient with a testicular tumour may suggest the presence of a non-seminomatous component, although pathology and other clinical findings are required.

AFP can be particularly useful for monitoring when it was elevated before treatment. A falling concentration may be consistent with treatment response, while a persistent or rising level may suggest residual, progressive, or recurrent disease.

Changes must be interpreted in relation to the expected biological decline of AFP, treatment timing, imaging findings, and liver status. A single small increase should not be used alone to determine treatment failure.

Different laboratories and analytical platforms may produce slightly different results. Serial monitoring is most informative when performed using the same method whenever possible.

Reference intervals vary according to age, pregnancy status, and laboratory method. The result should always be interpreted using the reference information printed on the individual report.

At Focus Diagnostics, AFP testing is performed using established immunoassay methods, calibrated analytical systems, and laboratory quality-control procedures to provide reliable results for specialist interpretation.